Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acamprosate reduces the craving for alcohol by decreasing glutamate activity and increasing gamma-aminobutyric acid (GABA)action in patients with alcohol dependence. Acamprosate has tolerable side effects that include diarrhea, headache, dizzinessand pruritus. In this study, we report acamprosate-induced extrapyramidal symptoms in an elderly patient with no history ofneurologic disease. Severe extrapyramidal symptoms developed two days after the administration of acamprosate and improvedover one week after the acamprosate was stopped. Extrapyramidal symptoms are commonly associated with dopamine receptorantagonists. However, there have been several reports of extrapyramidal symptoms occurring with drugs targeting other systems,including GABA, glutamate and serotonin. Acamprosate may decrease dopamine levels in the ventral tegmental area mediatedby glutamatergic action and thus cause extrapyramidal symptoms. We suggest that acamprosate carries the risk of causingextrapyramidal symptoms.
Abstract
Acamprosate reduces the craving for alcohol by decreasing glutamate activity and increasing gamma-aminobutyric acid (GABA)action in patients with alcohol dependence. Acamprosate has tolerable side effects that include diarrhea, headache, dizzinessand pruritus. In this study, we report acamprosate-induced extrapyramidal symptoms in an elderly patient with no history ofneurologic disease. Severe extrapyramidal symptoms developed two days after the administration of acamprosate and improvedover one week after the acamprosate was stopped. Extrapyramidal symptoms are commonly associated with dopamine receptorantagonists. However, there have been several reports of extrapyramidal symptoms occurring with drugs targeting other systems,including GABA, glutamate and serotonin. Acamprosate may decrease dopamine levels in the ventral tegmental area mediatedby glutamatergic action and thus cause extrapyramidal symptoms. We suggest that acamprosate carries the risk of causingextrapyramidal symptoms.
참고문헌 (9)
- Hunt WA., "Neuroscience research: how has it contributed to our understanding of alcohol abuse and alcoholism? A review", Alcohol Clin Exp Res, 17, pp.1055~1065 (1993)
- Bouza C, "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review", Addiction, 99, pp.811~828 (2004)
- Madhusoodanan S, "Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports", Ann Clin Psychiatry, 22, pp.148~156 (2010)
- Sidana AK, "Unusual side effects with acamprosate", Indian J Psychiatry, 49, pp.143~ (2007)
- Scott LJ, "Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence", CNS Drugs, 19, pp.445~464 (2005)
- Saivin S, "Clinical pharmacokinetics of acamprosate", Clin Pharmacokinet, 35, pp.331~345 (1998)
- Morales M, "Glutamate neurons within the midbrain dopamine regions", Neuroscience (2014)[DOI]
- Rayport S., "Glutamate is a cotransmitter in ventral midbrain dopamine neurons", Parkinsonism Relat Disord, 7, pp.261~264 (2001)
- Diana M, "Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats:electrophysiological and biochemical evidence", Proc Natl Acad Sci U S A, 90, pp.7966~7969 (1993)